A novel Omicron subvariant, BA.2, was found to be 1.5 times more transmissible than the original Omicron strain; analysis finds drugmakers increased list prices by 6.6% at the beginning of the year; alcohol consumption linked with the development of several cancer types.
As reported by CNBC, research on the Omicron subvariant, called BA.2, indicated that it is 1.5 times more transmissable than the original Omicron strain. As of this past Friday, the novel variant has been found in nearly half of US states and accounted for 127 cases nationwide, with other countries reporting growing circulation in proportion to Omicron. Although more infectious, early data has suggested that vaccines remain effective against the subvariant, with a booster dose shown to be 70% efficacious at preventing symptomatic illness.
According to findings of an analysis by Rx Savings Solutions, drugmakers increased list prices on cancer, diabetes, and other prescription drugs by 6.6% at the beginning of the year. Reported by The Wall Street Journal, 150 drugmakers raised prices on 866 products in the United States through January 20, in which price increases nearly matched the 7% overall consumer inflation rate—the highest rate in nearly 4 decades. Companies were found to keep most increases in the single digits as Congress continues to explore strategies to curb high drug costs.
Findings of a recent large-scale genetic study of Chinese adult populations linked the consumption of alcohol with the development of several types of cancer. As reported by Fox News, the main analysis focused primarily on men and investigated how the presence of specific alleles contributed to drinking habits. Data showed that the frequency of low-alcohol tolerability alleles was 21% for aldehyde dehydrogenase 2 and 69% for alcohol dehydrogenase 1B, with the low-tolerability alleles strongly linked to reduced alcohol consumption and lower cancer incidence in men. Overall, 7.4% of male participants developed cancer during the follow-up period.
Using AI for the Medical Note: Game Changer or a Bridge Too Far?
July 9th 2025During the “Tech Innovations in Community Oncology” meeting from Tennessee Oncology, oncologists explore artificial intelligence (AI) tools like DeepScribe to enhance documentation efficiency, reduce burnout, and improve patient engagement in clinical settings.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Insurance Gaps Threaten Cancer Treatment Success
July 7th 2025Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
Read More
How AI Can Address the Troubled Business Model in Oncology
July 7th 2025Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."
Read More